Literature DB >> 12888892

Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues.

Tetsuo Ohta1, Kohji Amaya, Shuangqin Yi, Hirohisa Kitagawa, Masato Kayahara, Itasu Ninomiya, Sachio Fushida, Takashi Fujimura, Gen-Ichi Nishimura, Koichi Shimizu, Koichi Miwa.   

Abstract

Hypovascularity is an outstanding characteristic of pancreatic ductal cancer by diagnostic imaging: most pancreatic ductal cancers are hypovascular or avascular, and tumor vessels are seldom seen on angiography. However, we found that the vasculature was not always poor on angiography of surgically resected specimens of locally advanced pancreatic ductal cancers. To elucidate these controversial findings, we focused on angiotensin II, a vasoconstrictor which is directly produced from angiotensinogen at acidic pH by active trypsin. We examined whether a local angiotensin II-generating system exists in pancreatic ductal cancer tissue. We measured angiotensin II concentration and angiotensin converting enzyme (ACE) activity in tissues from normal pancreas, pancreatic ductal cancers, colon cancers, and hepatocellular carcinomas. After surgically resected specimens were homogenized, angiotensin II concentration and ACE activity in tissues were measured using the florisil method and the Kasahara method, respectively. Tissue angiotensin II levels in pancreatic ductal cancer (n=13) were significantly higher than those of normal pancreas (n=7), colon cancers (n=7), or hepatocellular carcinomas (n=7). However, there was no significant difference in the ACE activity in tissue between them. This study provides in vivo evidence of an ACE-independent, angiotensin II-generating system in pancreatic ductal cancer tissues and suggests that locally formed angiotensin II may act on the pre-existing pancreatic arteries around the tumor, leading to formation of hypovascular or avascular regions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888892

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

Review 1.  Mechanism of cancer pain.

Authors:  Brian L Schmidt; Darryl T Hamamoto; Donald A Simone; George L Wilcox
Journal:  Mol Interv       Date:  2010-06

2.  Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver.

Authors:  Shir Lin Koh; E I Ager; P L N Costa; C Malcontenti-Wilson; V Muralidharan; C Christophi
Journal:  Clin Exp Metastasis       Date:  2014-01-18       Impact factor: 5.150

3.  Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells.

Authors:  Wen-Bin Liu; Xing-Peng Wang; Kai Wu; Ru-Ling Zhang
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

Review 4.  The renin-angiotensin system and cancer: old dog, new tricks.

Authors:  Amee J George; Walter G Thomas; Ross D Hannan
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

5.  Angiotensin-converting enzyme gene DD genotype neither increases susceptibility to acute pancreatitis nor influences disease severity.

Authors:  Nevin Oruc; Georgios I Papachristou; Haritha Avula; Adam Slivka; Janette Lamb; David C Whitcomb
Journal:  HPB (Oxford)       Date:  2009-02       Impact factor: 3.647

6.  Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil.

Authors:  Fereshteh Asgharzadeh; Niloufar Naghibzadeh; Milad Hashemzehi; Asma Mostafapour; Seyed Mahdi Hassanian; Amir Avan; Majid Khazaei
Journal:  J Gastrointest Cancer       Date:  2022-01-27

7.  Changes in the renin angiotensin system during the development of colorectal cancer liver metastases.

Authors:  Jaclyn H Neo; Eleanor I Ager; Peter W Angus; Jin Zhu; Chandana B Herath; Christopher Christophi
Journal:  BMC Cancer       Date:  2010-04-10       Impact factor: 4.430

8.  Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.

Authors:  Y Nakai; H Isayama; H Ijichi; T Sasaki; N Sasahira; K Hirano; H Kogure; K Kawakubo; H Yagioka; Y Yashima; S Mizuno; K Yamamoto; T Arizumi; O Togawa; S Matsubara; T Tsujino; K Tateishi; M Tada; M Omata; K Koike
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

9.  Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients.

Authors:  Hiroki Osumi; Satoshi Matsusaka; Takeru Wakatsuki; Mitsukuni Suenaga; Eiij Shinozaki; Nobuyuki Mizunuma
Journal:  Mol Clin Oncol       Date:  2015-08-31

Review 10.  Do proton pump inhibitors protect against cancer progression in GERD?

Authors:  Tomoharu Miyashita; Furhawn A Shah; John W Harmon; Guy P Marti; Daisuke Matsui; Koichi Okamoto; Isamu Makino; Hironori Hayashi; Katsunobu Oyama; Hisatoshi Nakagawara; Hidehiro Tajima; Hideto Fujita; Hiroyuki Takamura; Manabu Murakami; Itasu Ninomiya; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Tetsuo Ohta
Journal:  Surg Today       Date:  2012-10-31       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.